Article tools
Author information

Research Article

High efficiency of muscle regeneration after human myoblast clone transplantation in SCID mice.

J Huard, S Verreault, R Roy, M Tremblay and J P Tremblay

Centre de recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, Canada.

SCID mouse tibialis anterior muscles were first irradiated to prevent regeneration by host myoblasts and injected with notexin to damage the muscle fibers and trigger regeneration. The muscles were then injected with roughly 5 million human myoblasts. 1 mo later, 16-33% of the normal number of muscle fibers were present in the injected muscle, because of incomplete regeneration. However, > 90% of these muscle fibers contained human dystrophin. Some newly formed muscle fibers had an accumulation of human dystrophin and desmin on a part of their membrane. Such accumulations have been demonstrated at neuromuscular junctions before suggesting that the new muscle fibers are innervated and functional. The same pool of clones of human myoblasts produced only < or = 4% of muscle fibers containing human dystrophin when injected in nude mice muscles. Several of the human myoblasts did not fuse and remained in interstitial space or tightly associated with muscle fibers suggesting that some of them have formed satellite cells. Moreover, cultures of 98% pure human myoblasts were obtained from transplanted SCID muscles. In some mice where the muscle regeneration was not complete, the muscle fibers containing human dystrophin also expressed uniformly HLA class 1, confirming that the fibers are of human origin. The presence of hybrid muscle fibers containing human dystrophin and mouse MHC was also demonstrated following transplantation. These results establish that in absence of an immune reaction, transplanted human myoblasts participate to the muscle regeneration with a high degree of efficacy even if the animals were killed only 1 mo after the transplantation.

Browse pages

Click on an image below to see the page. View PDF of the complete article


Articles that cite this article:

A novel myogenic cell line with phenotypic properties of muscle progenitors
Serena Zacchigna, Even K. Østli, Nikola Arsic, Lucia Pattarini, Mauro Giacca, Srdjan Djurovic
J Mol Med 86(1):105. doi:10.1007/s00109-007-0268-0 [CrossRef]

Myogenic stem cells for the therapy of primary myopathies: wishful thinking or therapeutic perspective?
Giulio Cossu, Fulvio Mavilio
J Clin Invest 105(12):1669. doi:10.1172/JCI10376 [CrossRef]

Human muscular fetal cells: a potential cell source for muscular therapies
Nathalie Hirt-burri, Anthony S. Buys roessingh, Corinne Scaletta, Stefan Gerber, Dominique P. Pioletti, Lee Ann Applegate, Judith Hohlfeld
Pediatr Surg Int 24(1):37. doi:10.1007/s00383-007-2040-5 [CrossRef]

FK506 Immunosuppression to Control the Immune Reactions Triggered by First-Generation Adenovirus-Mediated Gene Transfer
Jean-Thomas Vilquin, Benoît Guérette, Ikuo Kinoshita, Brigitte Roy, Marlyne Goulet, Claude Gravel, Raynald Roy, Jacques P. Tremblay
Hum Gene Ther 6(11):1391. doi:10.1089/hum.1995.6.11-1391 [CrossRef]

<i>LacZ</i> Gene Transfer to Skeletal Muscle Using a Replication-Defective Herpes Simplex Virus Type 1 Mutant Vector
Johnny Huard, Giri Akkaraju, Simon C. Watkins, Michele Pike-cavalcoli, Joseph C. Glorioso
Hum Gene Ther 8(4):439. doi:10.1089/hum.1997.8.4-439 [CrossRef]